BioXcel Therapeutics Provides an Update on its Ongoing Phase 3 SERENITY Trials
BioXcel Therapeutics, Inc. (BTAI)
Last bioxcel therapeutics, inc. earnings: 11/14 07:00 am
Check Earnings Report
Company Research
Source: GlobeNewswire
More than one-third of the SERENITY I & II patients have been dosed, including over 100 bipolar patients On track to report topline data from both studies in mid-2020 NEW HAVEN, Conn., March 19, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced that more than one-third of the patients in the Phase 3 SERENITY trials have been enrolled and treated. To date, the company has not observed a change in enrollment rates resulting from the COVID-19 pandemic, and currently maintains previous guidance that SERENITY I & II are expected to be completed by mid-year 2020. “Despite the current situation with COVID-19, we remain on track with the enrollment of our SERENITY studies,” stated Vimal Mehta, Chief Executive Officer of BTI. “Up to now, all schizophrenia and bipolar patients enrolled have su
Show less
Read more
Impact Snapshot
Event Time:
BTAI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BTAI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BTAI alerts
High impacting BioXcel Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
BTAI
News
- BioXcel Therapeutics Announces Proposed Public OfferingGlobeNewswire
- BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ... [Yahoo! Finance]Yahoo! Finance
- BioXcel Therapeutics, Inc. (BTAI) Q3 2024 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- BioXcel Therapeutics Reports Third Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- BioXcel Therapeutics Reports Third Quarter 2024 Financial ResultsGlobeNewswire
BTAI
Earnings
- 11/14/24 - Beat
BTAI
Sec Filings
- 11/21/24 - Form 424B5
- 11/21/24 - Form 8-K
- 11/14/24 - Form 10-Q
- BTAI's page on the SEC website